



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Satoh et al.

Application No.: 10/004,645

Group Art Unit: 1653

Filed: December 4, 2001

Examiner: To Be Assigned

For: ANILINOPYRIMIDINE
DERIVATIVES AS JNK PATHWAY
INHIBITORS AND COMPOSITIONS AND
METHODS RELATED THERETO

Attorney Docket No.: 10624-050-999

**POWER OF ATTORNEY BY ASSIGNEE
AND EXCLUSION OF INVENTOR(S) UNDER 37 C.F.R. 3.71**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The undersigned assignee of the entire interest in the above-identified subject application hereby appoints: Berj A. Terzian (Reg. No. 20060), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), Thomas E. Friebe (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Samuel B. Abrams (Reg. No. 30605), Steven I. Wallach (Reg. No. 35402), Marcia H. Sundeen (Reg. No. 30893), Paul J. Zegger (Reg. No. 33821), Edmond R. Bannon (Reg. No. 32110), Bruce J. Barker (Reg. No. 33291), Adriane M. Antler (Reg. No. 32605), Thomas G. Rowan (Reg. No. 34419), James G. Markey (Reg. No. 31636), Thomas D. Kohler (Reg. No. 32797), Scott D. Stimpson (Reg. No. 33607), Gary S. Williams (Reg. No. 31066), Ann L. Gisolfi

(Reg. No. 31956), Todd A. Wagner (Reg. No. 35399), Scott B. Familant (Reg. No. 35514), Kelly D. Talcott (Reg. No. 39582), Francis D. Cerrito (Reg. No. 38100), Anthony M. Insogna (Reg. No. 35203), Brian M. Rothery (Reg. No. 35340), Brian D. Siff (Reg. No. 35679), Michael J. Lyons (Reg. No. 37386), Garland T. Stephens (Reg. No. 37242), William J. Sipio (Reg. No. 34514), Nikolaos C. George (Reg. No. 39201), Stephen S. Rabinowitz (Reg. No. 40286), Ognjan V. Shentov (Reg. No. 38051), and Kenneth L. Stein (Reg. No. 38704), all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006 and 3300 Hillview Avenue, Palo Alto, CA 94304, all of Pennie & Edmonds LLP (PTO Customer No. 20583), as its attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 C.F.R. 3.71, provided that, if any one of these attorneys ceases being affiliated with the law firm of Pennie & Edmonds LLP as partner, counsel, or employee, then the appointment of that attorney and all powers derived therefrom shall terminate on the date such attorney ceases being so affiliated.


An assignment of the entire interest in the above-identified subject application:

☐ was recorded on _____ at reel/frame ____/____.

☒ is submitted herewith for recording.

Please direct all correspondence for this application to customer no. 20583.

ASSIGNEE: Signal Pharmaceuticals, Inc.

Signature: 

Typed Name: Alan J. Lewis, Ph.D.

Position/Title: President

Address: 5555 Oberlin Drive

San Diego, California 92121

Date: 7/11/02



07-24-02

Express Mail No.: EL 477 038 003 US

RECEIVED
JUL 26 2002
TECH CENTER
1500/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Satoh et al.

Application No.: 10/004,645

Group Art Unit: 1653

Filed: December 4, 2001

Examiner: To be assigned

For: ANILINOPYRIMIDINE
DERIVATIVES AS JNK
PATHWAY INHIBITORS AND
COMPOSITIONS AND METHODS
RELATED THERETO

Attorney Docket No.: 10624-050-999

**TRANSMITTAL OF POWER OF ATTORNEY BY ASSIGNEE AND EXCLUSION
OF INVENTOR(S) UNDER 37 C.F.R. § 3.71**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants submit herewith a Power of Attorney by Assignee and Exclusion of Inventor(s) under 37 C.F.R. § 3.71 executed by Dr. Alan J. Lewis, President, Signal Pharmaceuticals, Inc., the Assignee of the entire interest in the above-identified patent application. Dr. Lewis is authorized to act on behalf of Signal Pharmaceuticals, Inc.

It is estimated that no fee is due in connection with this transmittal. In the event that a fee is required, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Anthony M. Insogna, Reg. No. 35,203
By: Matthew E. Lutz, Reg. No. 36,343
35,203

Date July 23, 2002

Anthony M. Insogna

(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090